HomeHealth NewsFDA proposes ban on bulk compounding of semaglutide and tirzepatide

FDA proposes ban on bulk compounding of semaglutide and tirzepatide

May 10, 2026

- Advertisement -

The FDA puts forward a move to exclude GLP-1 drugs from the bulk compounding list. Image credit: VICTOR TORRES/Stocksy

On April 30, 2026, the U.S. FDA announced it is considering removing GLP-1 medications from the 503B bulks list.
FDA’s 503B bulks list identifies drug substances that outsourcing facilities can use to compound medications.
Experts agree removing GLP-1s from the 503B bulks list will significantly lower the availability of compounded GLP-1s drugs.
Patients may still be able to…

- Advertisment -